News for Molecular Partners AG (0QXX.L)

Published at

May 19, 2025 8:15 AM

by gurufocus.com

positive

positive

Molecular Partners to Present at Upcoming Investor Conferences | MOLN Stock News

Molecular Partners AG (NASDAQ: MOLN) to participate in two key investor conferences in May 2025. Events include H.C. Wainwright 3rd Annual BioConnect an

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

May 19, 2025 8:00 AM

by gurufocus.com

positive

positive

Molecular Partners to Present at Upcoming Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; MOLN), a clinical-stage biotech company

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

May 15, 2025 11:00 PM

by gurufocus.com

neutral

neutral

Molecular Partners Reports Financial Results and Highlights from Q1 2025

Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Apr 25, 2025 11:15 PM

by gurufocus.com

positive

positive

Molecular Partners (MOLN) Unveils Promising Preclinical Data at AACR 2025 | MLLCF Stock News

Molecular Partners (MOLN) has announced the presentation of significant preclinical findings at the American Association for Cancer Research annual meeting 2025

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Apr 25, 2025 11:00 PM

by gurufocus.com

neutral

neutral

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Apr 22, 2025 11:00 PM

by gurufocus.com

neutral

neutral

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readou

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Apr 16, 2025 7:16 PM

by gurufocus.com

positive

positive

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting | MOLN Stock News

\n Molecular Partners (MOLN) shareholders approved all board proposals at the Annual General Meeting. The company reported a net loss of CHF 50.6 million f

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Apr 16, 2025 6:16 PM

by manilatimes.net

positive

positive

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

**media[597168]**

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Apr 3, 2025 3:55 PM

by zacks.com

positive

positive

Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Molecular Partners AG Sponsored ADR (MOLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Mar 8, 2025 8:02 AM

by gurufocus.com

positive

positive

Molecular Partners AG (MLLCF) (FY 2024) Earnings Call Highlights: Strategic Shifts and Financial Resilience

Revenue: CHF5 million in 2024, exclusively from the Novartis collaboration.Operating Expenses: CHF66 million, within the guidance range of CHF65 million to CHF

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Mar 8, 2025 6:06 AM

by gurufocus.com

positive

positive

Full Year 2024 Molecular Partners AG Earnings Call Transcript

Mar 07, 2025 / 01:00PM GMTOperator Good morning, and welcome to the Molecular Partners fourth quarter and full year 2024 results call. (Operator Instructions).

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Mar 7, 2025 5:59 PM

by seekingalpha.com

positive

positive

Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript

Molecular Partners AG (NASDAQ:MOLN) Q4 2024 Earnings Conference Call March 7, 2025 8:00 AM ETCompany ParticipantsMichael Tobias Stumpp - EVP ProjectsPatrick...

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Mar 6, 2025 10:17 PM

by manilatimes.net

mixed

mixed

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

**media[559663]**

AMGN MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Feb 28, 2025 7:00 AM

by gurufocus.com

positive

positive

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Participation in fireside chats at TD Cowen and Leerink healthcare conferencesCall on 2024 financial results on March 7 at 2.00 pm CET (8.00 am ET) ZURICH-SCHL

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Jan 15, 2025 9:04 PM

by seekingalpha.com

positive

positive

Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs (MOLN)

Molecular Partners' DARPin platform shows promise, but future funding is uncertain. Learn why MOLN stock could be a risky, but promising buy.

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Jan 12, 2025 7:00 PM

by gurufocus.com

positive

positive

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipel

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Jan 12, 2025 7:00 PM

by gurufocus.com

neutral

neutral

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenEx

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Dec 17, 2024 10:26 PM

by manilatimes.net

positive

positive

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

**media[494978]**

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Dec 17, 2024 10:00 PM

by gurufocus.com

positive

positive

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; MOLN), a clinical-stage biotech company

MOLN.SW MLLCF 0QXX.L

Read more →
Published at

Dec 13, 2024 3:55 PM

by zacks.com

neutral

neutral

Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet

The consensus price target hints at an 80.7% upside potential for Molecular Partners AG Sponsored ADR (MOLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MOLN.SW MLLCF 0QXX.L

Read more →